Treatment of older patients with mantle cell lymphoma in the era of novel agents

References

• National Cancer Institute. Surveillance, Epidemiology, and End Results program website. 2022. http://www.seer.cancer.gov
   Google Scholar
• Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720–1748. doi: 10.1038/s41375-022-01620-2.
   PubMed Web of Science ®Google Scholar
• Cohen PL, Kurtin PJ, Donovan KA, et al. Bone marrow and peripheral blood involvement in mantle cell lymphoma. Br J Haematol. 1998;101(2):302–310. doi: 10.1046/j.1365-2141.1998.00684.x.
   PubMed Web of Science ®Google Scholar
• Lamm W, Dolak W, Kiesewetter B, et al. Gastrointestinal involvement in patients with mantle cell lymphoma: a single center experience of Eighty-Five patients. Dig Dis. 2019;37(3):194–200. doi: 10.1159/000496508.
   PubMed Web of Science ®Google Scholar
• Ek S, Dictor M, Jerkeman M, et al. Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma. Blood. 2008; 15111(2):800–805. doi: 10.1182/blood-2007-06-093401.
   PubMed Web of Science ®Google Scholar
• Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol. 2009;27(8):1209–1213. Mar 10. →6. doi: 10.1200/JCO.2008.19.6121.
   PubMed Web of Science ®Google Scholar
• Preetesh Jain P, Wang M. Blastoid mantle cell lymphoma. Hematol Oncol Clin North Am. 2020;34(5):941–956. doi: 10.1016/j.hoc.2020.06.009.
   PubMed Web of Science ®Google Scholar
• Hoster E, Rosenwald A, Berger F, et al. Prognostic value of Ki-67 index, cytology, and growth pattern in Mantle-Cell lymphoma: results from randomized trials of the european mantle cell lymphoma network. J Clin Oncol. 2016;34(12):1386–1394. doi: 10.1200/JCO.2015.63.8387.
   PubMed Web of Science ®Google Scholar
• Eskelund CW, Dahl C, Hansen JW, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017;130(17):1903–1910. doi: 10.1182/blood-2017-04-779736.
   PubMed Web of Science ®Google Scholar
• Sarkozy C, Terré C, Jardin F, et al. Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index. Genes Chromosomes Cancer. 2014;53(1):106–116. doi: 10.1002/gcc.22123.
   PubMed Web of Science ®Google Scholar
• Hermine O, Hoster E, Walewski J, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL younger): a randomised, open-label, phase 3 trial of the european mantle cell lymphoma network. Lancet. 2016;388(10044):565–575. doi: 10.1016/S0140-6736(16)00739-X.
   PubMed Web of Science ®Google Scholar
• Eskelund CW, Kolstad A, Jerkeman M, et al. 15-year follow-up of the second nordic mantle cell lymphoma trial (MCL2): prolonged remissions without survival Plateau. Br J Haematol. 2016;175(3):410–418. doi: 10.1111/bjh.14241.
   PubMed Web of Science ®Google Scholar
• Chihara D, Cheah CY, Westin JR, et al. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD anderson cancer center. Br J Haematol. 2016;172(1):80–88. doi: 10.1111/bjh.13796.
   PubMed Web of Science ®Google Scholar
• Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111(2):558–565. doi: 10.1182/blood-2007-06-095331.
   PubMed Web of Science ®Google Scholar
• Hurria A, Lichtman SM. Clinical pharmacology of cancer therapies in older adults. Br J Cancer. 2008;98(3):517–522. doi: 10.1038/sj.bjc.6604201.
   PubMed Web of Science ®Google Scholar
• Soubeyran P, Fonck M, Blanc-Bisson C, et al. Predictors of early death risk in older patients treatd with first-line chemotherapy for cancer. J Clin Oncol. 2012;30(15):1829–1834. doi: 10.1200/JCO.2011.35.7442.
   PubMed Web of Science ®Google Scholar
• Dahi PB, Lee J, Devlin SM, et al. Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphoma. Blood Adv. 2021;5(12):2608–2618. doi: 10.1182/bloodadvances.2020004167.
   PubMed Web of Science ®Google Scholar
• Klener P, Fronkova E, Belada D, et al. Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma. Hematol Oncol. 2018;36(1):110–115. doi: 10.1002/hon.2483.
   PubMed Web of Science ®Google Scholar
• Robak T, Huang H, Jin J, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015;372(10):944–953. doi: 10.1056/NEJMoa1412096.
   PubMed Web of Science ®Google Scholar
• Flinn IW, van der Jagt R, Kahl B, et al. First-Line treatment of patients with indolent Non-Hodgkin lymphoma or Mantle-Cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-Year Follow-Up study. J Clin Oncol. 2019;37(12):984–991. doi: 10.1200/JCO.18.00605.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203–1210. doi: 10.1016/S0140-6736(12)61763-2.
   PubMed Web of Science ®Google Scholar
• Chiara Tisi M, Nassi L, Patti C, et al. Rituximab plus bendamustine and cytarabine (R-BAC) in elderly patients with newly diagnosed mantle cell lymphoma: long term follow-up and mrd results of a phase 2 study from the fondazione italiana linfomi. Blood. 2021;138(Supplement 1):384–384. doi: 10.1182/blood-2021-153364.
   Google Scholar
• Bega G, Olivieri J, Riva M, et al. Rituximab and bendamustine (BR) compared with rituximab, bendamustine, and cytarabine (R-BAC) in previously untreated elderly patients with mantle cell lymphoma. Cancers. 2021;13(23):6089. doi: 10.3390/cancers13236089.
   PubMed Web of Science ®Google Scholar
• Pal Singh S, Dammeijer F, Hendriks RW. Role of bruton’s tyrosine kinase in B cells and malignancies. Mol Cancer. 2018;17(1):57. doi: 10.1186/s12943-018-0779-z.
   PubMed Web of Science ®Google Scholar
• Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507–516. doi: 10.1056/NEJMoa1306220.
   PubMed Web of Science ®Google Scholar
• Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126(6):739–745. doi: 10.1182/blood-2015-03-635326.
   PubMed Web of Science ®Google Scholar
• Rule S, Dreyling M, Goy A, et al. Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis. Haematologica. 2019;104(5):e211–e214. doi: 10.3324/haematol.2018.205229.
   PubMed Web of Science ®Google Scholar
• Wang ML, Lee H, Chuang H, et al. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-Centre, open-label, phase 2 trial. Lancet Oncol. 2016;17(1):48–56. doi: 10.1016/S1470-2045(15)00438-6.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016;387(10020):770–778. doi: 10.1016/S0140-6736(15)00667-4.
   PubMed Web of Science ®Google Scholar
• Hess G, Rule S, Jurczak W, et al. Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus. Leuk Lymphoma. 2017;58(12):2824–2832. doi: 10.1080/10428194.2017.1326034.
   PubMed Web of Science ®Google Scholar
• Wang ML, Jurczak W, Jerkeman M, et al. Ibrutinib plus bendamustine and rituximab in untreated Mantle-Cell lymphoma. N Engl J Med. 2022;386(26):2482–2494. doi: 10.1056/NEJMoa2201817.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Inwards D. Acalabrutinib for mantle cell lymphoma. Blood. 2019;133(24):2570–2574. doi: 10.1182/blood.2019852368.
   PubMed Web of Science ®Google Scholar
• Wang M, Rule S, Zinzani PL, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018;391(10121):659–667. doi: 10.1016/S0140-6736(17)33108-2.
   PubMed Web of Science ®Google Scholar
• Wang M, Rule S, Zinzani PL, et al. Acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma: long-Term efficacy and safety results from a phase 2 study. Blood. 2020;136(Supplement 1):38–39. doi: 10.1182/blood-2020-134824.
   Google Scholar
• Tam CS, Opat S, Simpson D, et al. Zanubrutinib for the treatment of relapsed or25 refractory mantle cell lymphoma. Blood Adv. 2021;5(12):2577–2585. doi: 10.1182/bloodadvances.2020004074.
   PubMed Web of Science ®Google Scholar
• Song Y, Zhou K, Zou D, et al. Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. Blood. 2022;139(21):3148–3158. doi: 10.1182/blood.2021014162.
   PubMed Web of Science ®Google Scholar
• Zhou K, Zou D, Zhou J, et al. Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials. J Hematol Oncol. 2021;14(1):167. doi: 10.1186/s13045-021-01174-3.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Tam CS, Wang M, et al. A phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma. Future Oncol. 2021;17(3):255–262. doi: 10.2217/fon-2020-0794.
   PubMedGoogle Scholar
• Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021;397(10277):892–901. doi: 10.1016/S0140-6736(21)00224-5.
   PubMed Web of Science ®Google Scholar
• Eyre TA, Shah NN, Le Gouill S, et al. BRUIN MCL-321: a phase 3 Open-Label, randomized study of pirtobrutinib versus investigator choice of BTK inhibitor in patients with previously treated, BTK inhibitor naïve mantle cell lymphoma (trial in progress). Blood. 2021;138(Supplement 1):2422–2422. doi: 10.1182/blood-2021-145920.
   Google Scholar
• Davids MS, Roberts AW, Seymour JF, et al. Phase I first-in-Human study of venetoclax in patients with relapsed or refractory Non-Hodgkin lymphoma. J Clin Oncol. 2017;35(8):826–833. doi: 10.1200/JCO.2016.70.4320.
   PubMed Web of Science ®Google Scholar
• Tam CS, Anderson MA, Pott C, et al. Ibrutinib plus venetoclax for the treatment of Mantle-Cell lymphoma. N Engl J Med. 2018;378(13):1211–1223. doi: 10.1056/NEJMoa1715519.
   PubMed Web of Science ®Google Scholar
• Eyre TA, Walter HS, Iyengar S, et al. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after bruton tyrosine kinase inhibitor therapy. Haematologica. 2019;104(2):e68–e71. doi: 10.3324/haematol.2018.198812.
   PubMed Web of Science ®Google Scholar
• Wang M, Ramchandren R, Chen R, et al. Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study. J Hematol Oncol. 2021;14(1):179. doi: 10.1186/s13045-021-01188-x.
   PubMed Web of Science ®Google Scholar
• Gribben JG, Fowler N, Morschhauser F. Mechanisms of action of lenalidomide in B-Cell Non-Hodgkin lymphoma. J Clin Oncol. 2015;33(25):2803–2811. doi: 10.1200/JCO.2014.59.5363.
   PubMed Web of Science ®Google Scholar
• Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26(30):4952–4957. doi: 10.1200/JCO.2007.15.3429.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma. Ann Oncol. 2011;22(7):1622–1627. doi: 10.1093/annonc/mdq626.
   PubMed Web of Science ®Google Scholar
• Goy A, Sinha R, Williams ME, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol. 2013;31(29):3688–3695. doi: 10.1200/JCO.2013.49.2835.
   PubMed Web of Science ®Google Scholar
• Goy A, Kalayoglu Besisik S, Drach J, et al. Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trial. Br J Haematol. 2015;170(4):496–503. doi: 10.1111/bjh.13456.
   PubMed Web of Science ®Google Scholar
• Trněný M, Lamy T, Walewski J, et al. SPRINT trial investigators and in collaboration with the european mantle cell lymphoma network. Lenalidomide versus investigator’s choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial. Lancet Oncol. 2016;17(3):319–331. doi: 10.1016/S1470-2045(15)00559-8.
   PubMed Web of Science ®Google Scholar
• Rule S, Jan W, Aleksander S, et al. Quality of life in relapsed/refractory mantle cell lymphoma patients treated with lenalidomide vs investigator’s choice: MCL-002 (SPRINT) trial. Europ Haematol Assoc. 2015;17(3):319–331.
   Google Scholar
• Ruan J, Martin P, Christos P, et al. Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma. Blood. 2018;132(19):2016–2025. doi: 10.1182/blood-2018-07-859769.
   PubMed Web of Science ®Google Scholar
• Jerkeman M, Eskelund CW, Hutchings M, et al. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. Lancet Haematol. 2018;5(3):e109–e116. doi: 10.1016/S2352-3026(18)30018-8.
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Feldman SA, Zhao Y, et al. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother. 2009;32(7):689–702. doi: 10.1097/CJI.0b013e3181ac6138.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma. N Engl J Med. 2017;377(26):2531–2544. doi: 10.1056/NEJMoa1707447.
   PubMed Web of Science ®Google Scholar
• Lin RJ, Lobaugh SM, Pennisi M, et al. Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma. Haematologica. 2021;106(1):255–258. doi: 10.3324/haematol.2019.243246.
   PubMed Web of Science ®Google Scholar
• Ram R, Grisariu S, Shargian-Alon L, et al. Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients - a matched control multicenter cohort study. Haematologica. 2022;107(5):1111–1118. doi: 10.3324/haematol.2021.278288.
   PubMed Web of Science ®Google Scholar
• Denlinger N, Bond D, Jaglowski S. CAR T-cell therapy for B-cell lymphoma. Curr Probl Cancer. 2022;46(1):100826. doi: 10.1016/j.currproblcancer.2021.100826.
   PubMed Web of Science ®Google Scholar
• Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-Cell therapy in relapsed or refractory Mantle-Cell lymphoma. N Engl J Med. 2020;382(14):1331–1342. doi: 10.1056/NEJMoa1914347.
   PubMed Web of Science ®Google Scholar
• Wang M, Munoz J, Goy A, et al. Three-Year Follow-Up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including High-Risk subgroups, in the ZUMA-2 study. J Clin Oncol. 2022;40(16_suppl):7518–7518. doi: 10.1200/JCO.2022.40.16_suppl.7518.
   Google Scholar
• Iacoboni G, Rejeski K, Villacampa G, et al. Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv. 2022;6(12):3606–3610. doi: 10.1182/bloodadvances.2021006922.
   PubMed Web of Science ®Google Scholar
• Palomba ML, Gordon LI, Siddiqi T, et al. Safety and preliminary efficacy in patients with relapsed/refractory mantle cell lymphoma receiving lisocabtagene maraleucel in transcend NHL 001. Blood. 2020;136(Supplement 1):10–11. doi: 10.1182/blood-2020-136158.
   Google Scholar
• Di Blasi R, Le Gouill S, Bachy E, et al. Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis. Blood. 2022;140(24):2584–2593. doi: 10.1182/blood.2022016945.
   PubMed Web of Science ®Google Scholar
• Dickinson M, Carlo-Stella C, Morschhauser F, et al. Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and ≥ 2 prior therapies: pivotal phase II expansion results. J Clin Oncol. 2022;40(16_suppl):7500–7500. doi: 10.1200/JCO.2022.40.16_suppl.7500.
   Web of Science ®Google Scholar
• Phillips TJ, Dickinson M, Morschhauser F, et al. Glofitamab monotherapy induces high complete response rates in patients with heavily pretreated relapsed or refractory mantle cell lymphoma. Blood. 2022;140(Supplement 1):178–180. doi: 10.1182/blood-2022-157777.
   Google Scholar
• Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012;367(6):520–531. doi: 10.1056/NEJMoa1200920.
   PubMed Web of Science ®Google Scholar
• Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab after autologous Stem-Cell transplantation in Mantle-Cell lymphoma. N Engl J Med. 2017;377(13):1250–1260. doi: 10.1056/NEJMoa1701769.
   PubMed Web of Science ®Google Scholar
• Vidal L, Gafter-Gvili A, Dreyling M, et al. Maintenance treatment for patients with mantle cell lymphoma: a systematic review and meta-analysis of randomized trials. Hemasphere. 2018;2(4):e136. doi: 10.1097/HS9.0000000000000136.
   PubMed Web of Science ®Google Scholar
• Hill BT, Switchenko JM, Martin P, et al. Maintenance rituximab improves outcomes in mantle cell lymphoma patients who respond to induction therapy with bendamustine + rituximab without autologous transplant. Blood. 2019;134(Supplement_1):1525–1525. doi: 10.1182/blood-2019-129404.
   Google Scholar
• Rummel MJ, Knauf W, Goerner M, et al. Two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: first results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial). J Clin Oncol. 2016;34(15_suppl):7503–7503. doi: 10.1200/JCO.2016.34.15_suppl.7503.
   Web of Science ®Google Scholar
• Doorduijn JK, Zijlstra JM, Lugtenburg PJ, et al. Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial. Br J Haematol. 2020;190(3):385–393. doi: 10.1111/bjh.16567.
   PubMed Web of Science ®Google Scholar
• Kaplan LD, Maurer MJ, Stock W, et al. Bortezomib maintenance (BM) or consolidation (BC) following aggressive immunochemotherapy and autologous stem cell transplant (ASCT) for untreated mantle cell lymphoma (MCL): 8 year follow up of CALGB 50403 (alliance). Blood. 2018;132(Supplement 1):146–146. doi: 10.1182/blood-2018-99-112655.
   Google Scholar
• Ladetto M, Cortelazzo S, Ferrero S, et al. Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a fondazione italiana linfomi (FIL) multicentre, randomised, phase 3 trial. Lancet Haematol. 2021;8(1):e34–e44. doi: 10.1016/S2352-3026(20)30358-6.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Doorduijn JK, Eva Gine E, et al. Efficacy and safety of ibrutinib combined with standard First-Line treatment or as substitute for autologous stem cell transplantation in younger patients with mantle cell lymphoma: results from the randomized triangle trial by the european MCL network. Blood. 2022;140(Supplement 1):1–3. doi: 10.1182/blood-2022-163018.
   PubMedGoogle Scholar
• Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission. 2022. https://clinicaltrials.gov/ct2/show/NCT03267433
   Google Scholar
• Moore DC, Thompson D. A review of the bruton tyrosine kinase inhibitors in B-Cell malignancies. J Adv Pract Oncol. 2021;12(4):439–447.
   PubMedGoogle Scholar